<DOC>
	<DOCNO>NCT01959386</DOCNO>
	<brief_summary>This observational study evaluate efficacy , safety , tolerability patient report quality life Herceptin ( trastuzumab ) subcutaneous therapy patient HER2-positive early breast cancer routine clinical practice . Data eligible patient collect duration treatment ( approximately 1 year ) 1-2 year follow-up .</brief_summary>
	<brief_title>HerSCin : An Observational Study Herceptin ( Trastuzumab ) Subcutaneous Patients With HER2-Positive Early Beast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female male adult patient ; &gt; /= 18 year age Histologically confirm adenocarcinoma breast HER2positive tumor Eligible neoadjuvant adjuvant treatment Herceptin SC accord judgement physician Note : As patient recruitment ( date patient inform consent ) , retrospective documentation allow limited 9 week initial start therapy Herceptin SC Contraindications accord Summary Product Characteristics Herceptin SC Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>